Nurix Therapeutics outlines 2025 goals, objective
Initiate pivotal studies for NX-5948: Nurix is evaluating NX-5948 in an ongoing Phase 1b clinical trial in adults with relapsed or refractory B-cell malignancies and expects to initiate a suite of ...
I kept getting sicker. But you won’t catch me reaching for a tin foil hat
Within a few days, I was shunted out of the hospital with some meds, and pamphlets and told by a cardiologist who looked and ...
Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases
Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic ...